A $46M Bet on a New Way to Treat the Most Common Inherited Kidney Disease

Jan de Vries · 2026-08-07

When a biotech company lands a major funding round, it's usually a sign that something big is on the horizon. That's exactly what's happening with Mironid, a Glasgow-based biopharmaceutical firm that just closed a $46 million Series B financing round. The money is earmarked to push their lead drug candidate for Autosomal Dominant Polycystic Kidney Disease (ADPKD) through clinical development. ADPKD is a condition you might not hear about every day, but it's actually the most common hereditary kidney disorder in the world. Over 12 million people live with it, and the numbers are sobering: about half of those affected will develop kidney failure by the time they turn 60. That's a staggering statistic, and it's why this funding is more than just another headline in the biotech world. ### The Backing Behind the Breakthrough The round was led by the Scottish National Investment Bank, but they're not alone in this bet. A syndicate of existing backers also joined in, including the Roche Venture Fund, Epidarex Capital, Sofinnova Partners, BioGeneration Ventures, and the University of Strathclyde. When you see that kind of lineup, it tells you the science is credible and the potential is real. Neil Wilkie, Mironid's CEO, didn't mince words about what this means. "Securing funding from such a high-calibre syndicate is a strong validator of our approach to treating kidney diseases such as ADPKD," he said. "This financing will allow us to progress the clinical development of our lead candidate, bringing us closer to transforming the treatment landscape for patients with rare kidney diseases." ### A Decade in the Making Mironid didn't just appear out of thin air. The company was spun out of the University of Strathclyde and Heriot-Watt University back in 2015, building on more than three decades of research into PDE biology by Professor Miles Houslay. That's a long runway of foundational science, and it's now starting to pay off. The company is headquartered in Glasgow and focuses on developing drug candidates for degenerative and rare genetic kidney diseases, along with major inflammatory diseases and cancer. It's a broad pipeline, but the immediate priority is clear: getting their lead candidate through clinical trials. ### How the New Treatment Works So, what's the actual science here? Mironid's lead candidate is a first-in-class "LoAc" small molecule designed to target cyclic AMP (cAMP), a cellular signal that plays a role in all stages of ADPKD, from initiation through to end-stage disease. cAMP drives both cell proliferation and fluid secretion within the cysts, which is essentially what makes the disease progress. Here's the interesting part: preclinical data has shown significant efficacy and a favorable safety profile. The treatment has demonstrated reductions in cyst number and kidney volume. The company's argument is that by preventing new cyst formation and arresting the growth of existing ones, this cAMP-modulating approach could offer a more durable treatment option with an improved side-effect profile compared with existing therapies. That's a big claim, but the data seems to back it up so far. And it's not just about ADPKD. Mironid's pipeline also targets phosphodiesterase 4 (PDE4) enzymes, which are key players in cell signaling pathways implicated in disease progression. ### What This Means for Patients Paul Callaghan, Investment Director at the Scottish National Investment Bank, put it well: "Mironid exemplifies Scotland's growing reputation for biotech innovation, developing a new treatment approach that could improve options for people living with kidney disease." The fresh capital follows an earlier Series A extension round, bringing the company's total funding since inception to about $47 million. It's a solid war chest for a company at this stage. For the 12 million people worldwide living with ADPKD, this funding round is more than just a business transaction. It's a step closer to a treatment that could actually change the trajectory of the disease. And for the biotech industry, it's another reminder that patient-focused science, backed by patient investors, can move the needle on some of the toughest medical challenges we face. The road to commercialization is still long, but with this kind of backing, Mironid is in a strong position to make a real difference.